Niagen Bioscience, Inc.
NAGE- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001386570
No open-market purchases or sales by Niagen Bioscience, Inc. insiders were filed in the last 90 days; 139 institutions reported holding it in 13F filings for Q2 2026, worth $102.1M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −3 vs. previous quarter
- 139
- 13F valueReported value at the end of Q2 2026
- $102.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NAGE, Q2 2026
No superinvestor reported holding NAGE at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Niagen Bioscience, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 17, 2025 (view filing) | Nov 14 | 3 days | Pamir OzanChief Financial Officer | PPurchase | +4.46K | $6.81 | +$30.4K | +153.6%7.37K after | |
| Nov 17, 2025 (view filing) | Nov 14 | 3 days | Pamir OzanChief Financial Officer | PPurchase | +2.22K | $6.85 | +$15.2K | New position2.22K after | |
| Mar 10, 2025 (view filing) | Mar 7 | 3 days | Lopez Carlos LuisSVP, General Counsel | PPurchase | +273 | $7.86 | +$2.15K | +13.8%2.25K after | |
| Dec 13, 2024 (view filing) | Dec 13 | Same day | Jaksch Frank L JrDirector | SSale | −37.2K | $6.19 | −$230.0K | −13.2%244.2K after | |
| Nov 25, 2024 (view filing) | Nov 22 | 3 days | Pamir OzanChief Financial Officer | PPurchase | +2.91K | $7.36 | +$21.4K | New position2.91K after | |
| Aug 26, 2024 (view filing) | Aug 23 | 3 days | Patrick KristinDirector | SSale | −23.0K | $3.57 | −$82.1K | −100.0%0 after | |
| Aug 21, 2024 (view filing)6:15 AM ET | Aug 20 | 1 day | Li Ka Shing and 2 others10% Owner | SSale | −11.4M | – | – | −100.0%0 after | |
| Aug 21, 2024 (view filing)6:15 AM ET | Aug 20 | 1 day | Chau Hoi Shuen Solina Holly and 8 others10% Owner | PPurchase | +11.4M | – | – | +144.7%19.3M after | |
| Dec 4, 2023 (view filing) | Dec 1 | 3 days | Gerber BriannaChief Financial Officer | PPurchase | +5.00K | $1.41 | +$7.05K | +22.3%27.4K after | |
| Sep 7, 2023 (view filing)6:23 AM ET | Sep 6 | 1 day | Champion River Ventures Ltd and 3 othersDirector, 10% Owner | PPurchase | +3.47M | – | – | +43.7%11.4M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Niagen Bioscience, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,184,659 | $13.3M | 0.00% | +313,040+8.1% | Added |
| Steel Peak Wealth Management LLC | 3,500,129 | $11.2M | 0.29% | +127,129+3.8% | Added |
| Vanguard Capital Management LLC | 2,147,018 | $6.85M | 0.00% | −2,259−0.1% | Reduced |
| Tieton Capital Management, LLC | 2,008,470 | $6.41M | 1.84% | −20,685−1.0% | Reduced |
| Qube Research & Technologies Ltd | 1,625,016 | $5.18M | 0.01% | −89,623−5.2% | Reduced |
| Geode Capital Management, LLC | 1,478,603 | $4.72M | 0.00% | +133,682+9.9% | Added |
| UBS Group AG | 1,283,296 | $4.09M | 0.00% | −122,235−8.7% | Reduced |
| Goldman Sachs Group Inc | 1,262,743 | $4.03M | 0.00% | +10,784+0.9% | Added |
| Arrowstreet Capital, Limited Partnership | 1,171,215 | $3.74M | 0.00% | −1,207,222−50.8% | Reduced |
| Vanguard Portfolio Management LLC | 1,166,233 | $3.72M | 0.00% | −55,261−4.5% | Reduced |